---
input_text: 'Immunological efficacy of pneumococcal vaccination including the 13-valent
  pneumococcal vaccine in adult patients with sickle-cell disease: results of the
  randomized DREVAC controlled trial. BACKGROUND: Patients with sickle-cell disease
  (SCD) are at high risk for invasive pneumococcal diseases. The immunological efficacy
  of 13-valent conjugate pneumococcal vaccine (PCV13) followed by a 23-valent polysaccharide
  vaccine (PPSV23) is poorly documented in adults with SCD. METHODS: This was a randomized
  open-labelled phase 2 study of the immunogenicity of PCV13 at week (W)0, followed
  by PPSV23 at W4, compared to PPSV23 alone at W4 in adult patients with SCD. The
  proportion of responders (four-fold increase of serotype-specific IgG antibodies)
  to at least 10-shared serotypes was assessed at W8. Secondary endpoints were: i)
  geometrical mean titers (GMTs), ii) responders to 0-1, 2-5, 6-9, and 10-12 serotypes,
  iii) pneumococcal opsonophagocytic (OPA) activity, and iv) response durability at
  W24 and W96. RESULTS: In total, 128 patients were randomized in the PCV13/PPSV23
  (n=63) or PPSV23-alone groups (n=65). At W8, 24.56% and 8.20% of patients from the
  PCV13/PPSV23 and PPSV23 groups, respectively, reached the primary endpoint (p=0.016).
  These numbers were 36.2% and 8.7% for OPA responders (p=0.002). A combined PCV13/PPSV23
  strategy improved the breadth of responses to 0-1, 2-5, 6-9, and 10-12 serotypes
  with 15.8%, 35%, 24.6%, and 24.6% versus 52.5%, 31%, 8%, and 8% in the PPSV23 group.
  At W96, GMTs were significantly higher in the PCV13/PPSV23 than in the PPSV23 alone
  group for five serotypes (4, 14, 19A, 19F, 23F). CONCLUSIONS: A PCV13/PPSV23 regimen
  improved the breadth and magnitude of antibody responses against a large range of
  pneumococcal serotypes in adults with SCD. The sustainability of the immune response
  requires recall strategies.Clinical Trial Registration: NCT02274415.'
raw_completion_output: |-
  primary_disease: Sickle-cell disease
  medical_actions: Vaccination with 13-valent conjugate pneumococcal vaccine (PCV13); Vaccination with 23-valent polysaccharide vaccine (PPSV23); Assessment of serotype-specific IgG antibodies; Measurement of geometrical mean titers (GMTs); Assessment of pneumococcal opsonophagocytic (OPA) activity; Assessment of response durability
  symptoms: High risk for invasive pneumococcal diseases
  chemicals: 13-valent pneumococcal vaccine (PCV13); 23-valent polysaccharide vaccine (PPSV23)
  action_annotation_relationships: Vaccination with 13-valent conjugate pneumococcal vaccine (PCV13) PREVENTS High risk for invasive pneumococcal diseases IN Sickle-cell disease; Vaccination with 23-valent polysaccharide vaccine (PPSV23) PREVENTS High risk for invasive pneumococcal diseases IN Sickle-cell disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Vaccination with 23-valent polysaccharide vaccine (PPSV23) PREVENTS High risk for invasive pneumococcal diseases IN Sickle-cell disease

  ===

extracted_object:
  primary_disease: Sickle-cell disease
  medical_actions:
    - Vaccination with 13-valent conjugate pneumococcal vaccine (PCV13)
    - Vaccination with 23-valent polysaccharide vaccine (PPSV23)
    - Assessment of serotype-specific IgG antibodies
    - Measurement of geometrical mean titers (GMTs)
    - Assessment of pneumococcal opsonophagocytic (OPA) activity
    - Assessment of response durability
  symptoms:
    - High risk for invasive pneumococcal diseases
  chemicals:
    - 13-valent pneumococcal vaccine (PCV13)
    - 23-valent polysaccharide vaccine (PPSV23)
  action_annotation_relationships:
    - subject: MAXO:0001017
      predicate: PREVENTS
      object: High risk for invasive pneumococcal diseases
      qualifier: Sickle-cell disease
      subject_extension: 13-valent conjugate pneumococcal vaccine (PCV13)
    - subject: MAXO:0001017
      predicate: PREVENTS
      object: invasive pneumococcal diseases
      qualifier: Sickle-cell disease
      subject_qualifier: with 23-valent polysaccharide vaccine (PPSV23)
      object_qualifier: High risk
      subject_extension: 23-valent polysaccharide vaccine
      object_extension: High risk
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:81579
    label: erythropoietin
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0000756
    label: Blood transfusion
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0001297
    label: Stroke
  - id: HP:0002863
    label: Myelodysplastic syndrome
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:82594
    label: Ferritin
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: HP:0002140
    label: Ischemic Stroke
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MAXO:0009047
    label: total hip replacement
  - id: HP:0010885
    label: avascular necrosis
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:9168
    label: sirolimus
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000515
    label: Extracorporeal life support
  - id: HP:0001708
    label: Right ventricular failure
  - id: HP:0033515
    label: opioid dependence
  - id: MONDO:0005632
    label: Acute chest syndrome in sickle cell disease
  - id: HP:0001945
    label: fever
  - id: HP:0001878
    label: Hemolytic anemia
  - id: CHEBI:6121
    label: ketamine
  - id: CHEBI:17303
    label: morphine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0031274
    label: hypovolemic shock
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:18211
    label: citrulline
  - id: CHEBI:3638
    label: chloroquine
  - id: CHEBI:50733
    label: nutritional supplements
  - id: MONDO:0005570
    label: Blood disorders
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0100626
    label: end-stage liver disease
  - id: MONDO:0016363
    label: Iron overload diseases
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0002870
    label: obstructive sleep apnoea (OSA)
  - id: HP:0000520
    label: Proptosis
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000058
    label: pharmacological treatment
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: HP:0002878
    label: Acute respiratory failure
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitor
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: HP:0000112
    label: kidney disease
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000827
    label: serum ferritin measurement
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:4356
    label: <desferrioxamine (DFO)
  - id: CHEBI:17941
    label: deferiprone (DFP)
  - id: CHEBI:49005
    label: deferasirox (DFX)
  - id: CHEBI:38157
    label: iron chelators
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:9144
    label: silymarin
  - id: MAXO:0000750
    label: conditioning regimens (fludarabine-thiotepa-treosulfan, busulfan-cyclophosphamide)
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0100639
    label: erectile dysfunction
  - id: CHEBI:71940
    label: Tadalafil
  - id: CHEBI:71942
    label: PDE5 inhibitors
  - id: MONDO:0019740
    label: Acquired thrombotic thrombocytopenic purpura (aTTP)
  - id: CHEBI:24261
    label: Glucocorticoids
  - id: MAXO:0000194
    label: Opioid therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002315
    label: Headache
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: HP:0000832
    label: Primary hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:30660
    label: Thyroxine
  - id: HP:0001342
    label: Hemorrhagic strokes
  - id: HP:0002326
    label: Transient ischemic attack
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome
  - id: HP:0001923
    label: hemolysis (reticulocytosis)
  - id: MONDO:0800385
    label: Iron overload
  - id: CHEBI:6456
    label: Lidocaine
  - id: CHEBI:75008
    label: <visual analog pain scale (VAS)>
  - id: CHEBI:41264
    label: busulfan (Bu)
  - id: HP:0025322
    label: Venous occlusive disease (VOD)
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: HP:0002094
    label: dyspnea
  - id: MONDO:0007885
    label: Osteonecrosis of the Femoral Head (AVNFH)
  - id: HP:0000969
    label: Oedema
  - id: HP:0006554
    label: Acute Liver Failure
  - id: HP:0002098
    label: Respiratory distress
  - id: MAXO:0001175
    label: liver transplantation
  - id: MAXO:0010033
    label: umbilical cord blood transplantation
  - id: MAXO:0000068
    label: transplantation
  - id: CHEBI:17334
    label: penicillin
